Abbott Laboratories Q1 2026 Earnings Call Summary

Performance in the first quarter aligned with internal expectations, characterized by the strategic completion of the Exact Sciences acquisition to establish a high-growth beachhead in cancer diagnostics.
Medical Device growth of 8.5% was underpinned by double-digit performance in Electrophysiology, Heart Failure, and Rhythm Management, offsetting a weaker-than-expected respiratory testing season.
Nutrition results reflect a deliberate transition toward volume-driven growth following strategic pricing actions in 2025, with early data indicating that volume recovery is beginning to follow these adjustments.
The Core Lab Diagnostics business is navigating a recovery phase as it laps significant prior-year headwinds in China related to volume-based procurement (VBP) and post-COVID dynamics.
Management attributes the 7.5% growth in Diabetes Care to a temporary international tender renewal delay and a difficult year-over-year comparison involving 2025 shelf-restocking cycles.
Strategic positioning in Electrophysiology was bolstered by the earlier-than-planned launch of two new pulsed field ablation (PFA) catheters, Volt and TactiFlex Duo.

Full-year 2026 comparable sales growth is projected at 6.5% to 7.5%, assuming the full-year inclusion of Exact Sciences in both current and prior periods.
Management anticipates a growth acceleration in the second half of the year, driven by the normalization of Nutrition volumes and the broadening of new product launches in Electrophysiology.
Guidance for the remainder of the year adopts a conservative stance on respiratory testing, choosing not to forecast a compensatory strong season in Q4 following the weak Q1 results.
The Exact Sciences acquisition is expected to contribute approximately $3 billion in incremental sales for 2026, though it introduces a $0.20 dilutive impact to adjusted EPS due to financing costs.
Future growth in Diabetes Care is predicated on upcoming catalysts, including potential CMS coverage expansion for type 2 non-insulin users and the launch of a dual-analyte glucose-ketone sensor.

The acquisition of Exact Sciences closed on March 23, 2026, leading to the adoption of ‘comparable sales growth’ as the primary metric to provide an apples-to-apples portfolio view.
Financing costs related to the Exact Sciences transaction were absorbed earlier than originally planned, impacting first-quarter adjusted earnings per share.
Structural changes included moving the left atrial appendage (LAA) closure business from Structural Heart to Electrophysiology to better align with physician call points and accelerate adoption.
Management noted that while shipping lanes in the Middle East have become constrained, there has been no material impact on demand or reimbursement, with mitigation strategies focused on localized inventory.